Literature DB >> 17664231

Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage.

A M Bertoli1, L M Vila, M Apte, B J Fessler, H M Bastian, J D Reveille, G S Alarcon.   

Abstract

The objective of this study was to determine the factors predictive of time to the occurrence of pulmonary damage in systemic lupus erythematosus (SLE). Six-hundred and twenty-six SLE patients from a multiethnic (Hispanics, African Americans and Caucasians) longitudinal study of outcome were studied. Pulmonary damage was defined as per the Systemic Lupus International Collaborating Clinics Damage Index. Socioeconomic-demographic, clinical, genetic, serological features, pharmacologic treatments, behavioural, psychological and disease activity [as per the Systemic Lupus Activity Measure-Revised (SLAM-R)] were examined. Factors associated with time to the occurrence of pulmonary damage were examined by Cox proportional hazards regressions. A Kaplan-Meier survival curve was also examined. Forty-six (7.3%) patients had pulmonary damage after a mean (SD) total disease duration of 5.3 (3.6) years. Among those patients, 25 had pulmonary fibrosis, 12 pulmonary hypertension, eight pleural fibrosis, four pulmonary infarction and four shrinking lung syndrome. Seven patients had more than one type of lung damage. Cumulative rates of pulmonary damage at five and 10 years were 7.6% and 11.6%, respectively. In the multivariable analyses, age (HR = 1.033, 95% CI 1.006-1.060; P = 0.0170), pneumonitis (HR = 2.307, 95% CI 1.123-4.739; P = 0.0229) and anti-RNP antibodies (HR = 2.344, 95% CI 1.190-4.618; P = 0.0138) were associated with a shorter time to the occurrence of pulmonary damage while photosensitivity (HR = 0.388, 95% CI 0.184-0.818; P = 0.0128) and oral ulcers (HR = 0.466, 95% CI 0.230-0.942; P = 0.0335) with a longer time. Pulmonary damage is relatively common in SLE. Age, pneumonitis and anti-RNP antibodies were associated with a shorter time to the development of permanent lung disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17664231     DOI: 10.1177/0961203307079042

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

1.  Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities.

Authors:  Rajeev Saggar; Dinesh Khanna; Daniel E Furst; Shelley Shapiro; Paul Maranian; John A Belperio; Neeraj Chauhan; Philip Clements; Alan Gorn; S Sam Weigt; David Ross; Joseph P Lynch; Rajan Saggar
Journal:  Arthritis Rheum       Date:  2010-12

Review 2.  The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease.

Authors:  Alina Dima; Ciprian Jurcut; Cristian Baicus
Journal:  Rheumatol Int       Date:  2018-05-23       Impact factor: 2.631

3.  Prevalence of self-report photosensitivity in cutaneous lupus erythematosus.

Authors:  Kristen Foering; Renato Goreshi; Rachel Klein; Joyce Okawa; Mathew Rose; Andrew Cucchiara; Victoria P Werth
Journal:  J Am Acad Dermatol       Date:  2011-07-13       Impact factor: 11.527

4.  Reinforcing a medical hypothesis with a new question: is there a subgroup of shrinking lungs syndrome that is induced by pleurisy in systemic lupus erythematosus and is this subgroup marked by anti-Ro/SSA?

Authors:  Fabricio Souza Neves; Thais Helena Otto da Silva; Gislaine Paviani; Adriana Fontes Zimmermann; Glaucio Ricardo Werner de Castro; Ivânio Alves Pereira
Journal:  Clin Rheumatol       Date:  2010-03-20       Impact factor: 2.980

5.  Pulmonary manifestations in late versus early systemic lupus erythematosus: A systematic review and meta-analysis.

Authors:  Jennifer L Medlin; Karen E Hansen; Sara S McCoy; Christie M Bartels
Journal:  Semin Arthritis Rheum       Date:  2018-01-31       Impact factor: 5.532

6.  Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies.

Authors:  Lauren A Henderson; Stephen H Loring; Ritu R Gill; Katherine P Liao; Rumey Ishizawar; Susan Kim; Robin Perlmutter-Goldenson; Deborah Rothman; Mary Beth F Son; Matthew L Stoll; Lawrence S Zemel; Christy Sandborg; Paul F Dellaripa; Peter A Nigrovic
Journal:  J Rheumatol       Date:  2013-02-01       Impact factor: 4.666

7.  Severe cognitive dysfunction and shrinking lung syndrome in systemic lupus erythematous.

Authors:  Breno José Alencar Pires Barbosa; Francisco Akira Malta Cardozo; João Francisco Figueiredo Marcondes Ferraz; Jairo Rays; Márcia Yoshie Kanegae; Vilma Takayasu
Journal:  Autops Case Rep       Date:  2014-03-30

Review 8.  Shrinking lung syndrome in systemic lupus erythematosus: A case series and review of the literature.

Authors:  Helena Borrell; Javier Narváez; Juan José Alegre; Ivan Castellví; Francesca Mitjavila; María Aparicio; Eulàlia Armengol; María Molina-Molina; Joan M Nolla
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

9.  Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort.

Authors:  Javier Narváez; Helena Borrell; Fernando Sánchez-Alonso; Iñigo Rúa-Figueroa; Francisco Javier López-Longo; María Galindo-Izquierdo; Jaime Calvo-Alén; Antonio Fernández-Nebro; Alejandro Olivé; José Luis Andreu; Víctor Martínez-Taboada; Joan Miquel Nolla; José María Pego-Reigosa
Journal:  Arthritis Res Ther       Date:  2018-12-19       Impact factor: 5.156

10.  New-onset non-infectious pulmonary manifestations among patients with systemic lupus erythematosus in Sweden.

Authors:  Lindsy J Forbess; Marios Rossides; Michael H Weisman; Julia F Simard
Journal:  Arthritis Res Ther       Date:  2019-02-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.